Related Experiment Video

Updated: Jun 6, 2026

A Calcium Phosphate-Induced Mouse Abdominal Aortic Aneurysm Model
05:14

A Calcium Phosphate-Induced Mouse Abdominal Aortic Aneurysm Model

Published on: November 18, 2022

Angiotensin II type 1 receptor blocker inhibits arterial calcification in a pre-clinical model

Zachary B Armstrong1, Derek R Boughner, Maria Drangova

  • 1Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, The University of Western Ontario, Medical Sciences Building M426, London, ON, Canada.

Cardiovascular Research
|December 16, 2010
PubMed
Abstract

Insights

Angiotensin receptor blockers (ARBs) completely inhibited arterial calcification in a rabbit model by preventing vascular osteogenesis. This suggests ARBs may offer a novel therapeutic strategy for treating arterial calcification.

Area of Science:

  • Cardiovascular Research
  • Vascular Biology
  • Pharmacology

Background:

  • Arterial calcification is a significant predictor of mortality, often associated with various disorders.
  • Current understanding of arterial calcification mechanisms is incomplete, limiting effective pharmaceutical interventions.
  • No approved therapies exist to halt the progression of arterial calcification.

Purpose of the Study:

  • To investigate the efficacy of an angiotensin II (AngII) type 1 receptor blocker (ARB) in preventing arterial calcification.
  • To explore the potential of ARBs as a novel therapeutic approach for vascular calcification.

Main Methods:

  • Male New Zealand White rabbits were induced with atherosclerosis and arterial calcification via an atherogenic diet over 12 weeks.
  • An ARB was administered during the final 4 weeks of the study period.
  • Micro-computed tomography was employed to quantify arterial calcification, alongside molecular analysis of calcified regions.

Main Results:

  • The atherogenic diet led to extensive arterial calcification compared to controls.
  • Administration of the ARB completely inhibited arterial calcification (2.80 ± 1.17% vs. 0.01 ± 0.01% calcified tissue).
  • Molecular analysis revealed altered expression of bone morphogenetic protein 2, osteocalcin, AngII type 1 receptor, and α-smooth muscle actin, indicating vascular to osteoblast-like cell transition.

Conclusions:

  • Angiotensin receptor blockade effectively inhibits arterial calcification by disrupting vascular osteogenesis.
  • These findings present the first evidence supporting ARBs as a potential novel treatment for vascular calcification.
  • ARBs may represent a promising therapeutic option for patients with or at risk of arterial calcification.

More Related Videos

Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification08:55

Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification

Published on: November 20, 2017

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...